| ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers K Bergethon, AT Shaw, SH Ignatius Ou, R Katayama, CM Lovly, ... Journal of clinical oncology 30 (8), 863-870, 2012 | 1940 | 2012 |
| Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers R Katayama, AT Shaw, TM Khan, M Mino-Kenudson, BJ Solomon, ... Science translational medicine 4 (120), 120ra17-120ra17, 2012 | 1452 | 2012 |
| Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ... Cancer discovery 6 (10), 1118-1133, 2016 | 1096 | 2016 |
| The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer L Friboulet, N Li, R Katayama, CC Lee, JF Gainor, AS Crystal, ... Cancer discovery 4 (6), 662-673, 2014 | 902 | 2014 |
| Patient-derived models of acquired resistance can identify effective drug combinations for cancer AS Crystal, AT Shaw, LV Sequist, L Friboulet, MJ Niederst, EL Lockerman, ... Science 346 (6216), 1480-1486, 2014 | 783 | 2014 |
| Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK R Katayama, TM Khan, C Benes, E Lifshits, H Ebi, VM Rivera, ... Proceedings of the National Academy of Sciences 108 (18), 7535-7540, 2011 | 681 | 2011 |
| ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer JF Gainor, AM Varghese, SHI Ou, S Kabraji, MM Awad, R Katayama, ... Clinical cancer research 19 (15), 4273-4281, 2013 | 634 | 2013 |
| RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer MJ Niederst, LV Sequist, JT Poirier, CH Mermel, EL Lockerman, ... Nature communications 6 (1), 6377, 2015 | 579 | 2015 |
| Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F AT Shaw, L Friboulet, I Leshchiner, JF Gainor, S Bergqvist, A Brooun, ... New England Journal of Medicine 374 (1), 54-61, 2016 | 524 | 2016 |
| PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li, M West, RW Tang, ... Cancer cell 28 (1), 70-81, 2015 | 463 | 2015 |
| Acquired resistance to crizotinib from a mutation in CD74–ROS1 MM Awad, R Katayama, M McTigue, W Liu, YL Deng, A Brooun, ... New England Journal of Medicine 368 (25), 2395-2401, 2013 | 453 | 2013 |
| Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non–small-cell lung cancer LV Sequist, S Gettinger, NN Senzer, RG Martins, PA Jänne, R Lilenbaum, ... Journal of clinical oncology 28 (33), 4953, 2010 | 382 | 2010 |
| Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer K Uchibori, N Inase, M Araki, M Kamada, S Sato, Y Okuno, N Fujita, ... Nature communications 8 (1), 14768, 2017 | 373 | 2017 |
| Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels D Morishita, R Katayama, K Sekimizu, T Tsuruo, N Fujita Cancer research 68 (13), 5076-5085, 2008 | 342 | 2008 |
| Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib R Katayama, L Friboulet, S Koike, EL Lockerman, TM Khan, JF Gainor, ... Clinical cancer research 20 (22), 5686-5696, 2014 | 328 | 2014 |
| Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function Y Hao, K Sekine, A Kawabata, H Nakamura, T Ishioka, H Ohata, ... Nature cell biology 6 (9), 849-860, 2004 | 318 | 2004 |
| Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine R Katayama, CM Lovly, AT Shaw Clinical Cancer Research 21 (10), 2227-2235, 2015 | 273 | 2015 |
| Cabozantinib overcomes crizotinib resistance in ROS1 fusion–positive cancer R Katayama, Y Kobayashi, L Friboulet, EL Lockerman, S Koike, AT Shaw, ... Clinical cancer research 21 (1), 166-174, 2015 | 217 | 2015 |
| Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition R Katayama, A Aoyama, T Yamori, J Qi, T Oh-hara, Y Song, JA Engelman, ... Cancer research 73 (10), 3087-3096, 2013 | 214 | 2013 |
| Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer B Gong, K Kiyotani, S Sakata, S Nagano, S Kumehara, S Baba, B Besse, ... Journal of Experimental Medicine 216 (4), 982-1000, 2019 | 209 | 2019 |
